Cargando…
Effects of SARS-CoV-2 vaccine (Vero cells) on disease activity in patients with inflammatory bowel disease in China: a multicenter study
AIMS: To evaluate the impact of SARS-CoV-2 vaccine on IBD activity. METHODS: Adult IBD patients from five large IBD centers in China were enrolled and followed up for 6 months. Patients were divided into vaccinated and unvaccinated groups according to vaccination status. Demographic and clinical dat...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910246/ https://www.ncbi.nlm.nih.gov/pubmed/36757427 http://dx.doi.org/10.1007/s00384-023-04315-x |
_version_ | 1784884745280159744 |
---|---|
author | Zhang, Mingjun Huang, Qing Shi, Chenchen Feng, Yun Duan, Tianjiao Lin, Tianyu Zhu, Yuanmin Liu, Guisheng Li, Hongxia Liu, Yulan Jiang, Bo |
author_facet | Zhang, Mingjun Huang, Qing Shi, Chenchen Feng, Yun Duan, Tianjiao Lin, Tianyu Zhu, Yuanmin Liu, Guisheng Li, Hongxia Liu, Yulan Jiang, Bo |
author_sort | Zhang, Mingjun |
collection | PubMed |
description | AIMS: To evaluate the impact of SARS-CoV-2 vaccine on IBD activity. METHODS: Adult IBD patients from five large IBD centers in China were enrolled and followed up for 6 months. Patients were divided into vaccinated and unvaccinated groups according to vaccination status. Demographic and clinical data were collected. RESULTS: A total of 280 individuals (213 UC and 67 CD patients) were enrolled in the study. The unvaccinated and vaccinated groups of UC patients were comparable for basic characteristics, including age (t = − 0.8, p = 0.425), sex (χ(2) = 0.980, p = 0.322), course of disease (z = − 0.513, p = 0.608), surgical conditions (χ(2) = 1.042, p = 0.838), disease extent (χ(2) = 4.853, p = 0.088), or baseline drug therapy (χ(2) = 7.784, p = 0.064). In the subgroup of UC patients, there was no association between vaccination and disease activities, according to the medium disease activity scores for two groups: unvaccinated patients having scores (IQR) 1(2.75), 1(2), 1(2), and 1(2) at baseline, 1, 3, and 6 months, respectively, whereas vaccinated patients having scores (IQR) 1(2), 1(2), 1(2), and 1(2). Similar conclusions were also derived in the subgroup of CD patients. There were also no statistically significant differences in age (t = − 1.48, p = 0.144), sex (χ(2) = 0.003, p = 0.957), course of disease (z = − 0.074, p = 0.941), surgical conditions (χ(2) = 0.613, p = 0.594), localization (χ(2) = 6.261, p = 0.199), or baseline drug therapy (χ(2) = 5.881, p = 0.114) between 2 groups of CD patients. The medium disease activity scores (IQR) of the unvaccinated group at baseline, 1, 3, and 6 months were 1(4), 1(3), 1(3), and 1(3), respectively, whereas those of vaccinated group were 2.5(3.75), 2.5(3.75), 3(2), and 2(2), respectively. Overall, very few participants in this study described worsening IBD disease activity requiring a change or addition of medication. CONCLUSIONS: SARS-CoV-2 vaccine has no adverse effect on disease activity in IBD population. IBD patients should be recommended to receive SARS-CoV-2 vaccine in time. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00384-023-04315-x. |
format | Online Article Text |
id | pubmed-9910246 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-99102462023-02-10 Effects of SARS-CoV-2 vaccine (Vero cells) on disease activity in patients with inflammatory bowel disease in China: a multicenter study Zhang, Mingjun Huang, Qing Shi, Chenchen Feng, Yun Duan, Tianjiao Lin, Tianyu Zhu, Yuanmin Liu, Guisheng Li, Hongxia Liu, Yulan Jiang, Bo Int J Colorectal Dis Research AIMS: To evaluate the impact of SARS-CoV-2 vaccine on IBD activity. METHODS: Adult IBD patients from five large IBD centers in China were enrolled and followed up for 6 months. Patients were divided into vaccinated and unvaccinated groups according to vaccination status. Demographic and clinical data were collected. RESULTS: A total of 280 individuals (213 UC and 67 CD patients) were enrolled in the study. The unvaccinated and vaccinated groups of UC patients were comparable for basic characteristics, including age (t = − 0.8, p = 0.425), sex (χ(2) = 0.980, p = 0.322), course of disease (z = − 0.513, p = 0.608), surgical conditions (χ(2) = 1.042, p = 0.838), disease extent (χ(2) = 4.853, p = 0.088), or baseline drug therapy (χ(2) = 7.784, p = 0.064). In the subgroup of UC patients, there was no association between vaccination and disease activities, according to the medium disease activity scores for two groups: unvaccinated patients having scores (IQR) 1(2.75), 1(2), 1(2), and 1(2) at baseline, 1, 3, and 6 months, respectively, whereas vaccinated patients having scores (IQR) 1(2), 1(2), 1(2), and 1(2). Similar conclusions were also derived in the subgroup of CD patients. There were also no statistically significant differences in age (t = − 1.48, p = 0.144), sex (χ(2) = 0.003, p = 0.957), course of disease (z = − 0.074, p = 0.941), surgical conditions (χ(2) = 0.613, p = 0.594), localization (χ(2) = 6.261, p = 0.199), or baseline drug therapy (χ(2) = 5.881, p = 0.114) between 2 groups of CD patients. The medium disease activity scores (IQR) of the unvaccinated group at baseline, 1, 3, and 6 months were 1(4), 1(3), 1(3), and 1(3), respectively, whereas those of vaccinated group were 2.5(3.75), 2.5(3.75), 3(2), and 2(2), respectively. Overall, very few participants in this study described worsening IBD disease activity requiring a change or addition of medication. CONCLUSIONS: SARS-CoV-2 vaccine has no adverse effect on disease activity in IBD population. IBD patients should be recommended to receive SARS-CoV-2 vaccine in time. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00384-023-04315-x. Springer Berlin Heidelberg 2023-02-09 2023 /pmc/articles/PMC9910246/ /pubmed/36757427 http://dx.doi.org/10.1007/s00384-023-04315-x Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Research Zhang, Mingjun Huang, Qing Shi, Chenchen Feng, Yun Duan, Tianjiao Lin, Tianyu Zhu, Yuanmin Liu, Guisheng Li, Hongxia Liu, Yulan Jiang, Bo Effects of SARS-CoV-2 vaccine (Vero cells) on disease activity in patients with inflammatory bowel disease in China: a multicenter study |
title | Effects of SARS-CoV-2 vaccine (Vero cells) on disease activity in patients with inflammatory bowel disease in China: a multicenter study |
title_full | Effects of SARS-CoV-2 vaccine (Vero cells) on disease activity in patients with inflammatory bowel disease in China: a multicenter study |
title_fullStr | Effects of SARS-CoV-2 vaccine (Vero cells) on disease activity in patients with inflammatory bowel disease in China: a multicenter study |
title_full_unstemmed | Effects of SARS-CoV-2 vaccine (Vero cells) on disease activity in patients with inflammatory bowel disease in China: a multicenter study |
title_short | Effects of SARS-CoV-2 vaccine (Vero cells) on disease activity in patients with inflammatory bowel disease in China: a multicenter study |
title_sort | effects of sars-cov-2 vaccine (vero cells) on disease activity in patients with inflammatory bowel disease in china: a multicenter study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910246/ https://www.ncbi.nlm.nih.gov/pubmed/36757427 http://dx.doi.org/10.1007/s00384-023-04315-x |
work_keys_str_mv | AT zhangmingjun effectsofsarscov2vaccineverocellsondiseaseactivityinpatientswithinflammatoryboweldiseaseinchinaamulticenterstudy AT huangqing effectsofsarscov2vaccineverocellsondiseaseactivityinpatientswithinflammatoryboweldiseaseinchinaamulticenterstudy AT shichenchen effectsofsarscov2vaccineverocellsondiseaseactivityinpatientswithinflammatoryboweldiseaseinchinaamulticenterstudy AT fengyun effectsofsarscov2vaccineverocellsondiseaseactivityinpatientswithinflammatoryboweldiseaseinchinaamulticenterstudy AT duantianjiao effectsofsarscov2vaccineverocellsondiseaseactivityinpatientswithinflammatoryboweldiseaseinchinaamulticenterstudy AT lintianyu effectsofsarscov2vaccineverocellsondiseaseactivityinpatientswithinflammatoryboweldiseaseinchinaamulticenterstudy AT zhuyuanmin effectsofsarscov2vaccineverocellsondiseaseactivityinpatientswithinflammatoryboweldiseaseinchinaamulticenterstudy AT liuguisheng effectsofsarscov2vaccineverocellsondiseaseactivityinpatientswithinflammatoryboweldiseaseinchinaamulticenterstudy AT lihongxia effectsofsarscov2vaccineverocellsondiseaseactivityinpatientswithinflammatoryboweldiseaseinchinaamulticenterstudy AT liuyulan effectsofsarscov2vaccineverocellsondiseaseactivityinpatientswithinflammatoryboweldiseaseinchinaamulticenterstudy AT jiangbo effectsofsarscov2vaccineverocellsondiseaseactivityinpatientswithinflammatoryboweldiseaseinchinaamulticenterstudy |